Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study

Michele Cavo, Markus Hansson, Pieter Sonneveld, et al.

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskriftPeer review

74 Citeringar (SciVal)

Fingeravtryck

Fördjupa i forskningsämnen för ”Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study”. Tillsammans bildar de ett unikt fingeravtryck.

Medicin och livsvetenskap